Ameliorative potential of Blighia sapida K.D. Koenig bark against pancreatic β-cell dysfunction in alloxan-induced diabetic rats

J Complement Integr Med. 2017 Mar 17;14(3):/j/jcim.2017.14.issue-3/jcim-2016-0145/jcim-2016-0145.xml. doi: 10.1515/jcim-2016-0145.

Abstract

Background In West Africa, the fruit, seed, leaf and stem of Blighia sapida K.D. Koenig are commonly used as remedy against a variety of diseases, including diabetes mellitus. This study investigated the ameliorative potential of B. sapida K.D. Koenig stem bark ethanol extract against pancreatic β-cell dysfunction in diabetic rats. Methods Diabetes was induced by intraperitoneal injection of alloxan (65 mg/kg body weight) for 21 days, and orally administered with glibenclamide (5 mg/kg body weight), 50-150 mg/kg body weight of B. sapida stem bark ethanol extract once daily for 21 days. Results The blood glucose levels of rats induced with alloxan were significantly and gradually reduced (p<0.05) in B. sapida stem bark ethanol extract treated animals at the dose of 50-150 mg/kg body weight, and in glibenclamide-treated animals. The significant increase in the lipid peroxidation (malonaldehyde), homeostasis model assessment-insulin resistance scores (HOMA-IR) and decrease in serum insulin, pancreatic β-cell scores as well as antioxidant marker enzymes in untreated diabetic rats compared to normal control rats were reversed by the B. sapida stem bark ethanol extract and glibenclamide. Similarly, histopathological changes in the pancreas were also reversed by the extract and glibenclamide. However, these effects were most prominent in the animals treated with 150 mg/kg body weight of B. sapida bark. Conclusions These findings indicate that B. sapida stem bark possess anti-hyperglycemic activity and exhibits ameliorative potential in managing diabetes.

Keywords: Blighia sapida K.D. Koenig ethanol extract; antioxidant enzymes; diabetes; insulin resistance; pancreatic β-cell function.

MeSH terms

  • Alloxan
  • Animals
  • Blighia*
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / physiopathology
  • Drug Administration Schedule
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / physiology
  • Phytotherapy*
  • Plant Bark*
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use*
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Plant Extracts
  • Alloxan